Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b study of STA363 against herniated discs in Poland

Next Previous
Search
Trial Profile

A phase 1b study of STA363 against herniated discs in Poland

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lactic acid (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions
  • Acronyms herniated disc study

    • Most Recent Events

    • 25 Feb 2025 According to a Stayble Therapeutics media release, scientific abstract form this trial were submitted at the USASP (United States Association for the Study of Pain) and has been accepted for presentation in conference in the spring.
    • 25 Feb 2025 Status changed from active, no longer recruiting to completed, according to a Stayble Therapeutics media release.
    • 01 Feb 2025 According to a Stayble Therapeutics media release, company today provides an update on the ongoing work to establish partnerships for the pain treatment STA363 and the Board and management assess that there are good opportunities to enter into a partnership agreement based on the available Phase 1b results.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top